•  

Trends in Use of and Reproductive Outcomes Associated With Intracytoplasmic Sperm Injection (Jan 2015)

 

jama
Title:
Trends in Use of and Reproductive Outcomes Associated With Intracytoplasmic Sperm Injection
Journal:
JAMA. 2015;313(3):255-263
Author(s):
Sheree L. Boulet, DrPH, MPH1; Akanksha Mehta, MD1,2; Dmitry M. Kissin, MD, MPH1,3; Lee Warner, PhD1; Jennifer F. Kawwass, MD1,3; Denise J. Jamieson, MD, MPH1,3
Author(s) affiliation:
1Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia
2Department of Urology, Emory University School of Medicine, Atlanta, Georgia
3Department of Obstetrics and Gynecology, Emory University School of Medicine, Atlanta, Georgia
 

 

Short description:
The introduction of intracytoplasmic sperm injection (ICSI) in 1992 revolutionized the treatment of couples with male factor infertility and made paternity possible for a large proportion of men with nonobstructive azoospermia, or no measurable sperm count. Over the past 2 decades, the use of ICSI for patients with borderline or even normal semen characteristics has increased, without clear evidence of a benefit to using ICSI over conventional in vitro fertilization (IVF). The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology concluded that there is insufficient evidence to support the routine use of ICSI in patients without male factor infertility.7 Although ICSI may have a role in IVF cycles using preimplantation genetic testing, in vitro maturation, or previously cryopreserved oocytes, the routine use of ICSI for these indications requires further investigation.
Link to the journal
 

 

Abstract taken from PubMed

Importance:
Intracytoplasmic sperm injection (ICSI) is increasingly used in patients without severe male factor infertility without clear evidence of a benefit over conventional in vitro fertilization (IVF).
Objective:
To assess national trends and reproductive outcomes for fresh IVF cycles (embryos transferred without being frozen) following the use of ICSI compared with conventional IVF with respect to clinical indications for ICSI use.
Design, Settings, and Populations:
Retrospective cohort study using data on fresh IVF and ICSI cycles reported to the US National Assisted Reproductive Technology Surveillance System during 1996-2012.
Main Outcomes and MEasures:
Trends in ICSI use during 1996-2012 with respect to male factor infertility, unexplained infertility, maternal age 38 years or older, low oocyte yield, and 2 or more prior assisted reproductive technology cycles; reproductive outcomes for conventional IVF and ICSI cycles during 2008-2012, stratified by the presence or absence of male factor infertility.
Results:
Of the 1,395,634 fresh IVF cycles from 1996 through 2012, 908,767 (65.1%) used ICSI and 499,135 (35.8%) reported male factor infertility. Among cycles with male factor infertility, ICSI use increased from 76.3% (10,876/14,259) to 93.3% (32,191/34,506) (P < .001) during 1996-2012; for those without male factor infertility, ICSI use increased from 15.4% (4197/27,191) to 66.9% (42,321/63,250) (P < .001). During 2008-2012, male factor infertility was reported for 35.7% (176,911/494,907) of fresh cycles. Among those cycles, ICSI use was associated with a lower multiple birth rate compared with conventional IVF (30.9% vs 34.2%; adjusted relative risk [RR], 0.87; 95% CI, 0.83-0.91). Among cycles without male factor infertility (n = 317,996), ICSI use was associated with lower rates of implantation (23.0% vs 25.2%; adjusted RR, 0.93; 95% CI, 0.91-0.95), live birth (36.5% vs 39.2%; adjusted RR, 0.95; 95% CI, 0.93-0.97), and multiple live birth (30.1% vs 31.0%; adjusted RR, 0.93; 95% CI, 0.91-0.95) vs conventional IVF.
Conclusions:
Among fresh IVF cycles in the United States, ICSI use increased from 36.4% in 1996 to 76.2% in 2012, with the largest relative increase among cycles without male factor infertility. Compared with conventional IVF, ICSI use was not associated with improved postfertilization reproductive outcomes, irrespective of male factor infertility diagnosis.
Link to the paper on PubMed
Comment in:
 




IVF-Worldwide.com endeavors to ensure that the information in this article is accurate,reliable and up to date. However, the information is provided "as is" without warranty of any kind. IVF-Worldwide does not accept any responsibility or liability for the accuracy,content, completeness, legality, or reliability of the information contained in this article.
IVF-Worldwide.com is not responsible for the content of other websites linked to or referenced from this website. The website does not endorse the information, content,presentation or accuracy of such other websites and does not make any warranty,express or implied, regarding them.